KRAS and colorectal cancer: Recently, Roper et al. have also demonstrated that combined PI3K and MEK inhibition with NVP-BKM120 and PD-0325901 induced tumor regression in a mouse model of PIK3CA wild-type and KRAS mutant colorectal cancer [41].